Jazz Pharma

$156.01 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Jazz Pharma

Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.

Stock Analysis

last close $156.01
1-mo return 4.2%
3-mo return 0.2%
avg daily vol. 522.07T
52-week high 186.22
52-week low 117.64
market cap. $9.6B
forward pe 8.9
annual div. -
roe -11.7%
ltg forecast 7.4%
dividend yield -
annual rev. $2.8B
inst own. 96.8%
baraka

Subscribe now for daily local and international financial news

Subscribe